PRISM-MEL-301 (IMC-F106C-301) https://www.nct-dresden.de/en/trials/900-000002403 https://www.nct-dresden.de/@@site-logo/logo-nct.svg PRISM-MEL-301 (IMC-F106C-301) Category Skin tumors Subcategory Other dermatological tumors, Melanoma Trial Type First-Line-Therapy (Metastatic Disease/Hematology) Description for experts A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301) Description for laymen
